Evosep
Evosep creates fresh approaches to make clinical proteomics 10 times quicker and 100 times more reliable. We have a highly ambitious business plan to bring the community closer to the clinic, and we are aiming to meet the growing need for throughput with solid solutions for clinical and large-scale proteomics. We are critically considering the necessary system topologies for effective sample separation prior to mass spectrometric analysis and basing our design on years of expertise with nano-UHPLC R&D and application assistance.
Evosep creates fresh approaches to make clinical proteomics 10 times quicker and 100 times more reliable. We have a highly ambitious business plan to bring the community closer to the clinic, and we are aiming to meet the growing need for throughput with solid solutions for clinical and large-scale proteomics. We are critically considering the necessary system topologies for effective sample separation prior to mass spectrometric analysis and basing our design on years of expertise with nano-UHPLC R&D and application assistance.
Evosep has raised $40.0M across 1 round. Its most recent round was a Series Unknown of $40.0M in Jan 2023. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Evosep is featured in
Similar companies
Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived from the Technical University of Denmark, this Danish biotech spin-out has established a biotech framework that employs fungi to generate exceptional and eco-friendly colorants.
Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
SNIPR Biome operates a discovery stage biotechnology company aiming to transform microbial disease treatment. Using CRISPR technology, the company can manipulate bacterial CRISPR machinery to target and eradicate harmful bacteria in vivo, creating medicines that specifically kill bacteria with certain DNA sequences for healthcare professionals.
Streaks AI is a leading developer of conversational AI platforms, pioneering innovative solutions for seamless and interactive communication. Specialising in creating advanced conversational interfaces, Streaks AI leverages artificial intelligence to enhance user experiences across various industries.
Cellugy is a biotechnology company that is changing industrial materials using biofabricated cellulose. With significant funding and a defined path for expansion, they are implementing EcoFLEXY in various industries like personal care and packaging to support environmental sustainability and combat plastic pollution.
Evaxion Biotech A/S is a company in the clinical stage that uses AI-immunology™ platform to understand the human immune system in order to create new immunotherapies for cancer and infectious diseases. They are working on a variety of product candidates, including personalized cancer immunotherapies that are currently in Phase I/IIa clinical trials, and vaccines for bacterial and viral infections, such as Methicillin-resistant S. aureus.
Neurescue, a company from Denmark that specializes in medical devices, is creating cardiovascular devices for emergency patients. Their initial product, the safeREBOA device, is the first computer-assisted catheter for aortic occlusion. The company aims to expand the use of intelligent procedures in the future.
Enduro Genetics is a genetic technology company dedicated to facilitating biomanufacturing, collaborating with clients to enhance current or novel cell lines and production strains. Utilizing the Enduro Sense technology platform, they create genetic enhancements that enhance the productivity and stability of cell lines and production strains. This technology offers significant advancements for both established and emerging bioprocesses.
Commit Biologics is a biotechnology research company that was established in 2021 and is based in Aarhus, Denmark. They are focused on developing an innovative immunotherapy platform aimed at treating cancer.
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
Hervolution Therapeutics focuses on developing first-in-class immunotherapies to combat tumors from within. The company leverages Human Endogenous Retroviral proteins (HERVs) to create rationally designed immune therapeutics targeting the dark genome. Hervolution Therapeutics aims to address hidden enemies within the human body by pioneering innovative biotechnology solutions.
Antag Therapeutics is a biotechnology company developing metabolic and anti-obesity therapeutic drugs. It offers the development of peptide-based GIP receptor antagonists in order to monitor dietary-related metabolic diseases through the infusion to decrease blood flow and lipid uptake in adipose tissue.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.